Michael Heneka to Neuroprotective Agents
This is a "connection" page, showing publications Michael Heneka has written about Neuroprotective Agents.
Connection Strength
0.265
-
Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, Petri S, Meyer T, Grosskreutz J, Schrank B, Boentert M, Emmer A, Hermann A, Zeller D, Prudlo J, Winkler AS, Grehl T, Heneka MT, Wolleb?k Johannesen S, G?ricke B. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018 08; 17(8):681-688.
Score: 0.143
-
Sundararajan S, Jiang Q, Heneka M, Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int. 2006 Jul; 49(2):136-44.
Score: 0.062
-
Sch?tz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Sch?rmann B, Zimmer A, Heneka MT. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005 Aug 24; 25(34):7805-12.
Score: 0.059